Depression — clinical major depressive disorder — is the leading cause of disability worldwide, affecting an estimated 280 million people globally. It is characterised not by sadness alone but by a constellation of cognitive, emotional, physical, and motivational symptoms that profoundly impair functioning and quality of life. Yet despite being one of the most studied and best-understood psychiatric conditions, depression remains severely undertreated — with the World Health Organization estimating that more than 75% of people with depression in low- and middle-income countries receive no treatment at all.
Recognising Depression
The DSM-5 diagnostic criteria for major depressive disorder require five or more of the following symptoms, present during the same two-week period, representing a change from previous functioning, with at least one being depressed mood or loss of interest: depressed mood most of the day, nearly every day; markedly diminished interest or pleasure in activities (anhedonia); significant weight change or appetite disturbance; insomnia or hypersomnia; psychomotor agitation or retardation observable by others; fatigue or loss of energy; feelings of worthlessness or excessive guilt; difficulty thinking, concentrating, or making decisions; and recurrent thoughts of death or suicidal ideation. Critically, depression is not a character weakness or lack of willpower — it is a medical condition with identifiable neurobiological underpinnings including altered monoamine neurotransmission, HPA axis dysregulation, and structural brain changes.
Treatment
Multiple evidence-based treatments are available, with effect sizes comparing favourably to those of most medical interventions for chronic disease. Psychotherapy: CBT is the most extensively studied; it identifies and restructures depressive cognitive patterns and behavioural withdrawal cycles. Behavioural Activation — a specific CBT component emphasising re-engagement with rewarding activities — is effective as a standalone treatment. Interpersonal Therapy (IPT) and Problem-Solving Therapy are also empirically validated. Antidepressants: SSRIs and SNRIs are first-line medications with meaningful efficacy, particularly for moderate-to-severe depression. Response rates of 50–60% are typical; remission rates of 30–40% with first-line medication. Switching medications or augmentation strategies (lithium, atypical antipsychotics) improve outcomes for non-responders. Combined treatment produces superior outcomes to either modality alone for most presentations. Newer approaches — ketamine/esketamine for treatment-resistant depression, transcranial magnetic stimulation (TMS) — offer effective options for those who do not respond to conventional treatments.
Frequently Asked Questions
How is depression different from sadness?
Sadness is a normal emotional response to loss, disappointment, or difficult circumstances — it is proportionate, time-limited, and does not prevent all positive emotion. Depression is persistent (lasting weeks to months), pervasive across all aspects of life, frequently accompanied by anhedonia (inability to feel pleasure), physical symptoms, and often disproportionate to circumstances. The distinction matters because depression responds to treatment while sadness does not require it.
Can exercise treat depression?
Yes, to a meaningful degree. A 2023 meta-analysis of 218 studies (14,170 participants) found exercise produced a large antidepressant effect comparable to psychotherapy and approximately 60–70% of the effect of antidepressant medications. Mechanisms include increased BDNF (neurotrophic factor supporting neuroplasticity), normalisation of HPA axis activity, improved sleep, and self-efficacy benefits. Exercise is most effective as an adjunct to established treatments rather than a standalone replacement.
Sources
- WHO. Depression fact sheet. 2023.
- Cuijpers P, et al. Psychotherapy for Depression. JAMA Psychiatry. 2019.
- Noetel M, et al. Effect of exercise for depression. BMJ. 2024.